Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $7.1 million.

  • Apellis Pharmaceuticals' Change in Accured Expenses fell 5680.71% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year decrease of 7541.28%. This contributed to the annual value of $18.2 million for FY2024, which is 4806.29% down from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Change in Accured Expenses is $7.1 million, which was down 5680.71% from $22.9 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year Change in Accured Expenses high stood at $65.3 million for Q2 2021, and its period low was -$64.6 million during Q3 2021.
  • In the last 5 years, Apellis Pharmaceuticals' Change in Accured Expenses had a median value of $7.1 million in 2025 and averaged $1.9 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Change in Accured Expenses skyrocketed by 1541567.7% in 2021 and then crashed by 74268.89% in 2023.
  • Over the past 5 years, Apellis Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $31.7 million in 2021, then plummeted by 52.83% to $15.0 million in 2022, then fell by 20.74% to $11.9 million in 2023, then crashed by 48.7% to $6.1 million in 2024, then increased by 16.37% to $7.1 million in 2025.
  • Its Change in Accured Expenses stands at $7.1 million for Q3 2025, versus $22.9 million for Q2 2025 and -$30.2 million for Q1 2025.